Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-10-04

Clinical Trial Update: Study of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-041/KEYNOTE-041) [Phase 1]

View source ↗

Summary

Phase 1 study of pembrolizumab in advanced melanoma completed; results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Melanoma | Phase 1 | Status: COMPLETED | Results posted: 2016-10-04